Ignite Creation Date:
2024-10-26 @ 3:40 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06604767
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-17
Brief Title:
Study of a Respiratory Syncytial VirusHuman MetapneumovirusParainfluenza Virus Type 3 Vaccine Candidate in Adults Aged 60 Years and Older
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase 1 Dose-Escalation Randomized Active-Controlled Modified Double-Blind Parallel-Group Multi-Arm Study to Investigate the Safety and Immunogenicity of a Combined Respiratory Syncytial VirusHuman MetapneumovirusParainfluenza Virus Type 3 Vaccine Candidate in Adult Participants Aged 60 Years and Older
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this phase 1 study is to evaluate whether the vaccine is safe and can help the body to develop germ fighting agents called antibodies immunogenicity against the respiratory syncytial virus RSV human metapneumovirus hMPV and parainfluenza virus type 3 PIV3 The study will use different doses of PIV3 only and different combinations of RSVhMPVPIV3 or RSVhMPV or only RSV vaccine in adults aged 60 years and older
Detailed Description:
The study duration will be up to approximately 12 months minus the screening period
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None